Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypereosinophilic Syndrome 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

fludarabine 10ruxolitinib 9fludarabine phosphate 9Whole-Body Irradiation 9Specimen Handling 9Cyclophosphamide 8Azacitidine 8Mycophenolic Acid 7Cytarabine 7Busulfan 7Biopsy 7Tacrolimus 6venetoclax 5Stem Cell Transplantation 5Sirolimus 5Peripheral Blood Stem Cell Transplantation 5Injections 5Granulocyte Colony-Stimulating Factor 5Melphalan 4Cyclosporine 4CPX-351 4luspatercept 3ivosidenib 3decitabine and cedazuridine drug combination 3Thiotepa 3Methotrexate 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pevonedistat × 90 days × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡